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Abstract
Objectives To examine the effect of including bupr-
enorphine with detomidine for sedation of horses
undergoing clinical procedures.
Study design Partially blinded, randomised, pro-
spective clinical field trial.
Animals Eighty four client-owned horses scheduled
for minor surgery or diagnostic investigation under
standing sedation.
Methods The effects of buprenorphine (5 lg kg1)
(Group B, n = 46) or placebo (5% glucose solu-
tion) (Group C, n = 38) in combination with
detomidine (10 lg kg1) were compared in stand-
ing horses undergoing minor clinical procedures.
The primary outcome measure was successful
completion of the procedure. The degree of seda-
tion and ataxia were scored using simple descrip-
tive scales. Heart and respiratory rates were
recorded at 15–30 minute intervals. Parametric
data from each group were compared using ANOVA
or t-test and non parametric data using the
Mann–Whitney U test.
Results The procedure was carried out success-
fully in 91% of Group B and 63% of Group C
(p < 0.01). Repeat dosing was required in 24% of
Group B and 32% of Group C (p < 0.05). Sedation
was more profound and lasted longer (60 versus
45 minutes) in Group B (p < 0.01). Ataxia
occurred after detomidine, increased after bupr-
enorphine but not glucose administration, was
more profound in group B and lasted longer (60
versus 30 minutes) p < 0.001). Heart and
respiratory rates remained within normal limits
in both groups and there were no serious adverse
events.
Conclusions and clinical relevance Buprenorphine
5 and 10 lg kg1 enhanced the sedation pro-
duced by detomidine 10 and 20 lg kg1 with
minor side effects similar to other alpha2 agonist/
opioid combinations. Detomidine–buprenorphine
sedation is suitable for standing procedures in
horses.
Keywords alpha2 adrenoceptor agonist, buprenor-
phine, detomidine, equine, opioid, sedation.
Introduction
Numerous diagnostic and minor surgical procedures
are performed on sedated, standing horses because
general anaesthesia carries a substantial risk of
mortality and morbidity in this species (Johnston
et al. 2004). General anaesthesia also requires
appropriate facilities and expertise as well as incur-
ring considerable cost.
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Acepromazine and the alpha2 adrenoceptor
agonists are the most common individual agents
used for chemical restraint, but it is well recognized
that addition of an opioid enhances their sedative
effects without seriously compromising vital func-
tion (Clarke & Paton 1988; Taylor & Clarke 2007).
Alpha2 adrenoceptor agonist combinations using
xylazine, detomidine or romifidine have been
described with a number of different opioids given
as a bolus injection (Muir et al. 1979; Robertson &
Muir 1983; Taylor & Clarke 2007) or by infusion for
longer procedures (Hainisch 2001; Ringer et al.
2012a,b; 2013). In the UK at least, detomidine or
romifidine with butorphanol are probably the most
commonly used for sedation from a simple bolus
injection (Taylor et al. 1988; Browning & Collins
1994). Both combinations have UK Market
Authorization.
Buprenorphine hydrochloride (Vetergesic Multi-
dose; Alstoe Ltd, UK) has recently received UK
Market Authorization for analgesia and as an
adjunct to sedation in horses. Buprenorphine is
generally regarded as a partial mu (OP3)-agonist
opioid and is used widely for analgesia and sedation
in cats and dogs as well as laboratory animals and
exotics (Roughan & Flecknell 2002). A number of
investigations document buprenorphine’s effect in
horses: in accordance with this class of drug, in
normal, pain-free, research animals it produces
antinociception and some sympathetic and locomo-
tor stimulation (Carregaro et al. 2006, 2007; Love
et al. 2012). Combinations of buprenorphine (4–
10 lg kg1) with sedatives have also been evaluated
under laboratory conditions, showing opioid-
enhancement of xylazine, detomidine and romifidine
sedation similar to that of other opioids (Nolan &
Hall 1984; Love 2009; Cruz et al. 2011; Love et al.
2011a,b). One investigation has examined the use of
buprenorphine for sedation under clinical conditions
(van Dijk et al. 2003). Detomidine (10 lg kg1) and
buprenorphine (6 lg kg1) were given prior to
laparoscopy and sedation was maintained by con-
tinuous infusion of detomidine. The combination
was effective for the purposes, and there were no
adverse effects.
Studies investigating buprenorphine–detomidine
sedation after injection only for a range of common
clinical procedures have not yet been published. This
study describes a field trial which examined the
effects of inclusion of buprenorphine with detomi-
dine for sedation of horses undergoing clinical
procedures.
Materials and methods
Study design
A prospective, multi-centre, placebo-controlled
investigation of buprenorphine’s effects on detomi-
dine sedation was carried out in 86 client-owned
horses undergoing clinical diagnostic or surgical
procedures in general practices in the UK. The study
was carried out in accordance with Good Clinical
Practice (CVMP/VICH/595/98) under Animal Test
Certificate (ATC) as part of the registration process
for Market Authorisation. Informed owner consent
was obtained in all cases.
Horses
Horses admitted to one of seven participating UK
equine clinics were randomly allocated (block ran-
domisation, GraphPad Prism; GraphPad Software
Inc., CA, USA) to receive either buprenorphine
(group B) or 5% glucose placebo (group C) in addition
to detomidine for standing sedation to enable a
diagnostic or minor surgical procedure to be carried
out. All horses admitted for such treatment were
eligible, but were excluded if they had been heavily
sedated in the previous week, had cardiac dysrrhyth-
mias, colic, impaired respiratory or liver function,
were pregnant or lactating, or were under treatment
with sympathomimetic amines, potentiated sulph-
onamides or drugs causing respiratory depression.
Other antibiotics, non steroidal anti-inflammatory
agents and intravenous fluids were permitted. Food
was withheld at least four hours prior to treatment
and was made available again after recovery. Water
was available ad libitum prior to treatment and after
recovery.
Drug treatment
All horses were sedated with 10 lg kg1 detomidine
hydrochloride (Domosedan; Pfizer Ltd, UK) given by
slow intravenous (IV) injection 3–5 minutes before
administration of the test/control substance (BorG):
either 5 lg1 buprenorphine (Vetergesic Multidose;
Alstoe Ltd, UK) (group B) or an equivalent volume
(0.8 mL 50 kg1) of 5% glucose solution (Baxter
Healthcare Ltd, UK) (group C). If, 10 minutes after
administration of the BorG, sedation was judged
inadequate to carry out the procedure, then the
doses of detomidine and BorG were repeated at the
same time interval. If, 10 minutes after administra-
© 2013 Association of Veterinary Anaesthetists and the American College of Veterinary Anesthesia and Analgesia, 41, 14–24 15
Detomidine-buprenorphine sedation in horses P Taylor et al.
tion of the second doses, sedation was judged still to
be inadequate to carry out the procedure, rescue
sedation was implemented.
If rescue sedation was required, this was recorded,
and the horse withdrawn from further participation
in the study. The identity of the BorG was revealed,
and further sedation at the discretion of the veter-
inarian responsible for the case was given.
At each clinic, the identity of the BorG injection
was withheld from the assessor by using a dispenser,
who drew up the appropriate BorG solution into an
unidentified syringe for IV administration. The
assessor undertook all the assessments without
knowing the identity of the BorG solution adminis-
tered. Buprenorphine and glucose solutions were
clear and colourless, administered on the basis of
0.8 mL 50 kg1, making it impossible to distinguish
visually between them.
Assessments
The depth of sedation and degree of ataxia were
assessed using simple descriptive scales (SDS,
Table 1) prior to and at 15, 30, 45, 60, 90 and
120 minutes after the injection of BorG. Heart and
respiratory rates were also recorded at the same time
points. The primary outcome measure was overall
success of the procedure assessed on a scale of 1–4
(score 1–2 = success, score 3–4 = unsuccessful)
(Table 1).
Statistical analysis
The null hypothesis was that there would be no
statistical difference in primary outcome measure
between the groups indicating that buprenorphine
did not confer additional sedative effect over that of
detomidine alone. Power calculations (GraphPad
StatMate; GraphPad Software Inc) were based on
data describing sedation of horses using butorphanol
and detomidine (Taylor et al. 1988) and in donkeys
comparing detomidine with detomidine/butorpha-
nol (Joubert et al. 1999) and expecting buprenor-
phine and detomidine to provide a similar effect
(Love et al. 2011a,b). A sample size of 50 in each
group gave 80% power to detect a 20% difference in
the proportion of cases in groups B and C scored as
successful or unsuccessful, with p < 0.05, whilst still
allowing for withdrawal of 10 cases in each group.
Interim analysis of the data after 86 horses had
completed the trial indicated that the null hypothesis
should be rejected and the trial was stopped.
All data were analysed using GraphPad Prism
software. Normally distributed data are presented as
mean  SD. Categorical data are presented as pro-
portions within each category in each group. The
primary outcome (success or failure) was analysed
using Fisher’s exact test. Other non parametric
categorical data were analysed using Fisher’s exact
test for 2 9 2 contingency tables (requirement for
second dose) or the Chi-squared test for larger tables
(gender, breed, procedure). The Mann–Whitney U
test was used to compare overall sedation and ataxia
scores in each group; if a significant difference was
indicated, the proportion of horses in each group
awarded each score was compared using the
Table 1 Simple descriptive scale (SDS) scoring system for
sedation, ataxia and overall outcome. All assessors gained
experience in the SDS systems prior to trial data collection.
Assessments falling between descriptors were awarded the
higher score
Score Signs
Sedation
0 No sedation. Animal is alert, with normal
posture and response to contact with
assessor. Normal objection to intervention
1 Mild sedation. Low head carriage, relaxed facial
muscles and pendulous lower lip. Some
response to intervention
2 Moderate sedation. Head lowered towards
ground and swaying of hind legs. Slight
response to intervention
3 Marked sedation. Attempts to or becomes
recumbent. No response to intervention
Ataxia
0 No ataxia. Animal stands and walks
normally; is able to turn tightly
1 Mild ataxia. Animal able to walk, but some
lack of limb control
2 Moderate ataxia. Animal can walk only with
support, staggers but saves itself from falling
3 Marked ataxia. Animal is unable to walk without
danger of falling, staggers, falls if turned
Overall outcome
1 Satisfactory (procedure carried out easily with
no interference from the horse)
2 Acceptable (procedure completed fairly easily,
but with some interference from the
horse’s response)
3 Not satisfactory (procedure completed but with
some difficulty due to interference
from the horse)
4 Impossible (procedure had to be abandoned
due to lack of sedation) Outcome score
1–2 = success, score 3–4 = failure)
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Chi-squared test for each time point. Within each
group, changes in sedation and ataxia scores over
time were examined using the Kruskall Wallis test
(Freidman’s test was not used as the group sizes were
uneven); if a significant difference was indicated,
Dunn’s test was used to compare each time point
with pre-sedation values, and to compare post-
detomidine with post-BorG injection values. Single
parametric data from each group (body weight, age)
were compared using an unpaired t-test. Heart rate
and respiratory rates in each group were compared
using two way repeated measures ANOVA; no signif-
icant differences were detected, so no post hoc
analyses were performed (less than five horses in
each group were excluded due to missing data
points). Within each group, changes in heart and
respiratory rates over time were compared using one
way repeated measures ANOVA; where a significant
difference was indicated Dunnett’s test was used to
assess changes from pre-sedation baseline values,
and Tukey’s MCT was used to compare post-detom-
idine and post-BorG injection values. p < 0.05 was
considered significant.
Results
Animals
Data from 84 horses were analysed (n = 46 group B,
n = 38 group C). Two horses were rejected at
recruitment, one due to respiratory disease and the
other as it had been heavily sedated within the last
seven days. Data on gender, breed, procedure, body
weight and age are shown in Table 2. There were no
significant differences between the groups in any of
these variables.
Primary outcome measure
The procedure was carried out successfully (primary
outcome measure) in 42 horses in group B (91%)
and in 24 horses (63%) in group C (p = 0.0027),
therefore the null hypothesis was rejected and
buprenorphine was shown to enhance the sedation
produced by detomidine alone (Fig. 1).
A second dose of detomidine and BorG was
required in 11 horses in group B (24%) and 12 in
group C (32%) because of inadequacy of sedation at
10 minutes (p = 0.6248). The procedure was sub-
sequently completed satisfactorily after the second
dose in all horses in group B (outcome score 1 in six
horses and 2 in five horses). However, five group C
Table 2 Mean  SD body weight and age; and gender,
breed and procedure performed in 84 horses after sedation
with either detomidine and buprenorphine (group B) or
detomidine and 5% glucose solution (group C)
Group B (n = 46) Group C (n = 38)
Gender
14 Mares 19 Mares
26 Geldings 15 Geldings
6 Entire male 4 Entire male
Breed
7 Thoroughbred &
Thoroughbred cross
9 Thoroughbred &
Thoroughbred cross
6 Sport horse &
Warmblood
8 Sport horse &
Warmblood
15 Pony 11 Pony
8 Cob 5 Cob
Body weight
10 Cross breed & others 5 Cross breed & others
498  114 kg 496  106 kg
Age
10.5  5.7 years (median 10) 5.6  5.6 years
(median 10)
Procedure performed
10 Clipping 7 Clipping
3 Farriery 2 Farriery
9 Dentistry 3 Dentistry
17 Imaging* 15 Imaging*
7 Minor surgery with
local anaesthesia
11 Minor surgery with local
anaesthesia
*Imaging = radiography, ultrasound, MRI, endoscopy. No signif-
icant differences between groups: gender p = 0.1847, breed
p = 0.5964, body weight p = 0.9402, age p = 0.9382, procedure
p = 0.4036.
Figure 1 Primary outcome. Proportion of 84 horses after
sedation with detomidine followed by buprenorphine
(n = 46) or glucose (n = 38) with successful or failed
completion of the procedure. Significant difference between
the groups (p = 0.0027). Success = score 1 & 2, Fai-
lure = score 3 & 4.
© 2013 Association of Veterinary Anaesthetists and the American College of Veterinary Anesthesia and Analgesia, 41, 14–24 17
Detomidine-buprenorphine sedation in horses P Taylor et al.
horses requiring the second dose received an out-
come score of 4, and the procedure was either
abandoned or rescue sedation given. Two further
horses had outcome score 3, three score 2 and two
score 1. Rescue sedation was given to five horses in
group C with either a further 5 lg kg1 buprenor-
phine (two horses) or 20 lg kg1 detomidine and
40 lg kg1 butorphanol (two horses) or 50 lg kg1
romifidine and 13 lg kg1 butorphanol. Procedures
were subsequently carried out successfully in all
these five horses and there were no adverse effects.
Some additional doses of sedative were given
outwith the protocol. Three horses, (two group B,
one group C), were given a second dose of sedation
more than 10 minutes after the first BorG injection
because sedation was judged adequate at 10 min-
utes, but proved inadequate during the following
30–60 minutes. This allowed the procedure to be
carried out satisfactorily (outcomes 1&2). A further
horse in group B was given only detomidine for its
second dose, which proved inadequate. This was the
only horse in group B awarded an outcome score 4
and the procedure abandoned.
Sedation
Sedation developed immediately after injection of
detomidine and increased further after buprenor-
phine but not after glucose injection. Sedation
(scores significantly higher than pretreatment)
lasted 60 minutes in group B and 45 minutes in
group C. Overall sedation scores were higher in
group B than group C (p = 0.0086). A greater
proportion of the horses in group B were awarded
higher sedation scores than in group C at 15, 30 and
45 minutes. At all other time points the differences
were not significant (Fig. 2). Overall sedation in the
horses requiring a second dose of detomidine and
test drug at 10 minutes was not statistically different
from the overall sedation in those not requiring a
second dose in either group B (p = 0.6043) or group
C (p = 0.1459).
Ataxia
Ataxia developed immediately after injection of
detomidine and increased further after buprenor-
phine but not after glucose. Ataxia (scores signifi-
cantly higher than pretreatment) lasted 60 minutes
in group B and 30 minutes in group C. Overall
ataxia scores were higher in group B than in group C
(p = 0.0005). A greater proportion of the horses in
group B were awarded higher ataxia scores than in
group C at 15, 30 and 45 minutes after injection of
the test substance. At all other time points the
differences were not significant (Fig. 3). Overall
ataxia in the horses requiring a second dose of
detomidine and test drug at 10 minutes was not
statistically different from the overall ataxia in those
not requiring a second dose in either group B
(p = 0.4299) or group C (p = 0.7886).
Heart and respiratory rate
Heart rate decreased after detomidine injection in
both groups, and remained below pre-treatment
values until 45 minutes post BorG injection in group
B and until 30 minutes in group C (Fig. 4). Second
degree AV block developed after detomidine injection
in six horses in group B and two in group C. This
persisted for no more than 15 minutes after BorG
injection. There were no significant differences
between the two groups in heart rate and no values
were abnormally low or high.
Respiratory rate decreased after detomidine
injection in group B and was below pre-treatment
values from 30 to 120 minutes post buprenor-
phine injection (Fig. 5). Respiratory rate did not
change significantly from pre treatment values in
group C. There were no significant differences
between the two groups and few values were
abnormally low or high. Rates of 4 per minute
were recorded in two horses in group B, one of
these after detomidine, but before buprenorphine
was given. All increased to normal values within a
few minutes. A brief period (<3 minutes) of
tachypnoea (65 minute) was recorded in one
horse after buprenorphine.
Adverse events
There were no serious adverse events and few minor
unwanted effects in either group. Stertorious breath-
ing was noted in one group B horse which resolved
as sedation abated. Sedation was shorter than
desired in seven group C animals, and a twitch or
physical restraint was used to complete the proce-
dure in a further four cases (one group B, three
group C). One horse in group B was so heavily
sedated, or the analgesia so profound, that skin
lacerations during clipping went unnoticed. Four
cases in group B were initially too heavily sedated for
farriery or precise foot placement for imaging. Two
horses in group B were inadequately sedated after
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Figure 2 Distribution of simple descriptive scale (SDS) sedation scores in 84 horses after sedation with detomidine and
buprenorphine (n = 46) or glucose (n = 38). Overall sedation scores were higher in the buprenorphine group (p = 0.0086)
(Mann–Whitney U test). Groups were significantly different at 15 (p = 0.051), 30 (p = 0.029) and 45 (p = 0.034) minutes
(min) after test substance injection (Chi squared test).
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Figure 3 Distribution of simple descriptive scale (SDS) ataxia scores in 84 horses before and after sedation with detomidine
and buprenorphine (n = 46) or glucose (n = 38). Overall ataxia scores were higher in the buprenorphine group
(p = 0.0005) (Mann–Whitney U test). Groups were significantly different at 15 (p = 0.0003), 30 (p = 0.0179) and 45
(p = 0.0049) minutes (min) after test substance injection (Chi squared test).
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the first dose, became very ataxic after the second
dose of detomidine and no further buprenorphine
was given. The procedure was completed success-
fully in both cases.
Discussion
This field study demonstrated that buprenorphine
enhanced the sedation provided by detomidine alone
in common with the effects of other opioids used in
this way (Clarke & Paton 1988; Taylor et al. 1988;
Browning & Collins 1994). Longer procedures are
often carried out with infusions of alpha2 and opioid
combinations (Hainisch 2001; Ringer et al. 2012a,
b), and buprenorphine has been used in this way
with detomidine infusion (van Dijk et al. 2003).
However, the aim of our study was to evaluate the
effect of adding buprenorphine to detomidine when
given as a single injection rather than by infusion.
Some of the additional sedative effect seen with the
inclusion of buprenorphine in group B may been
related to better analgesia with the opioid. However,
since analgesia was not specifically evaluated, the
extent of such a contribution is unknown, and
probably minimal, as most of the procedures were
non painful.
The horses and ponies used in this investigation
were drawn from first opinion general practice and
were a fair representation of the UK equine popula-
tion likely to be treated under standing sedation in
routine equine practice. The two groups were well
matched and individual variation should not have
confounded the data. No attempt was made to score
individual temperament, the environmental condi-
tions or the invasiveness of the procedure. Whilst
these may have affected the degree of sedation, the
groups were equally represented in each clinic and
differences between treatments would not be
obscured.
The doses of detomidine and buprenorphine used
in this investigation were based on both previous
experience with other opioids used with alpha2
adrenoceptor agonists (Taylor et al. 1988; Brown-
ing & Collins 1994) as well as on laboratory data
from horses given buprenorphine with sedatives
(Love et al. 2011a,b). These investigations, and
studies of buprenorphine alone in horses (Carregaro
et al. 2006, 2007; Love et al. 2012), suggested that
doses of up to 10 lg kg1 buprenorphine would lead
to effective sedation when given with detomidine,
without serious adverse effects. Love’s studies (Love
et al. 2011a,b) also indicated that sedation was
improved if a larger dose of detomidine was given
when higher doses of buprenorphine were used. In
the present study, the initial 5 lg kg1 buprenor-
phine with 10 lg kg1 detomidine proved adequate
in most cases. However, when more profound
Figure 4 Mean  SD heart rate in 84 horses sedated with
detomidine and buprenorphine (n = 46) or glucose
(n = 38). No significant difference between groups. *
(buprenorphine group) and † (glucose group) = significant
(p < 0.05) decrease from pre treatment value.
Figure 5 Mean  SD respiratory rate in 84 horses sedated
with detomidine and buprenorphine (n = 46) or glucose
(n = 38). No significant difference between groups. *
(buprenorphine) = significant (p < 0.05) decrease from
pre treatment value. No significant change from pre-
treatment value in the glucose group.
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sedation was required, taking the total buprenor-
phine dose to 10 lg kg1, it was preceded by a
further dose of detomidine, taking its total to 20 lg
kg1, as suggested by Love’s data (Love et al.
2011b).
In the present study, the initial dose of 10 lg kg1
detomidine and 5 lg kg1 buprenorphine was suffi-
cient for successful completion of the procedure in
approximately three quarters of the cases. Addition of
the second dose of detomidine and buprenorphine
allowed the procedure to be carried out satisfac-
torily in all the remainder. The only failure in the
buprenorphine group was a horse given only detom-
idine in the second dosing. The procedure was
completed successfully in only around two-thirds of
the glucose group after the first dose of detomidine,
and after the second dosing there were still a few
horseswhere the procedurewas abandoned or rescue
sedationwas required. The data also indicate that the
quality of sedation was better after buprenorphine.
Effective sedation lasted for 60 minutes in the
buprenorphine group; additional sedation made
little impact on the effective duration as detected
by the sampling points. One hour of sedation is
probably sufficient for most common clinical proce-
dures carried out on standing horses. After sedation
with detomidine only, the effective sedation was only
45 minutes, and this proved inadequate in several
horses. The need for more sedation at 10 minutes
appeared to be related to the individual horse and
the proposed procedure, as overall sedation was not
increased in horses given a second dose compared
with those where one was sufficient.
Ataxia is always a potential hazard when standing
sedation is used in horses. This occurred in both
groups, but was more serious and long lasting after
buprenorphine. No horses fell, but two became
sufficiently ataxic after a second dose of detomidine
that the second dose of buprenorphine was withheld.
Second dosing of detomidine and BorG made little
impact on the duration of ataxia as detected by the
sampling points. After sedation with detomidine
only, ataxia lasted only 30 minutes whereas several
of the buprenorphine horses were still ataxic at
60 minutes. In previous laboratory studies (Love
et al. 2011b) sedation was better when higher doses
of both detomidine and buprenorphine were given
than when lower doses of detomidine were used with
higher doses of buprenorphine. However, the horses
in those studies were standing in stocks which may
have masked the ataxia. It is clear that, as with other
opioids (Clarke & Paton 1988), buprenorphine will
exacerbate the alpha2 adrenoceptor agonist-induced
ataxia, and care must be taken not to move a heavily
sedated horse or it may fall. Overall ataxia within
either group was not increased when a second dose
was given, suggesting that ataxia was related more
to the individual than to the actual dose of detom-
idine and buprenorphine.
There was little evidence of any serious cardio-
vascular or respiratory effects. Decreased heart
rate is a well known effect of alpha2 adrenoceptor
agonist administration and this was not enhanced.
Respiratory rate was lower in the buprenorphine
group, but the values were within a normal range
and this may simply reflect the degree of sedation
and lack of any anxiety. Second degree atrioven-
tricular block was seen in a few horses after the
detomidine injection. This is a well recognised
effect of alpha2 adrenoceptor agonists (Clarke &
Taylor 1986) and is not uncommon in normal
undisturbed horses standing quietly. Transient
tachypnoea was reported in one horse in the
buprenorphine group. It is difficult to ascertain
whether this was related to the buprenorphine as
it occurred only once. Opioids cause locomotor
activity and some stimulation in healthy, non
sedated horses (Carregaro et al. 2007) and the
transient tachypnoea may have been related to
this. Alternatively, it may simply have been a
response to the horse being startled as it recovered
from sedation. Stertorious breathing was seen in
one horse. This is not uncommonly seen with
alpha2 adrenoceptor agonist sedation as a result of
the low head position causing fluid accumulation
in the nasal mucous membranes. This can be
alleviated by raising the horse’s head to a more
normal position (Taylor & Clarke 2007).
Buprenorphine appeared to perform in a similar
manner to other opioids in enhancing sedation
(Clarke & Paton 1988). Use of opioids in horses
remains controversial because this class of drug may
cause locomotor stimulation and decreased gastro-
intestinal motility (Mama et al. 1992; Taylor et al.
2002; Senior et al. 2006). As a mu-agonist opioid,
buprenorphine presumably has similar potential.
Locomotor and sympathetic stimulation and
decreased abdominal auscultation scores were
reported after 5–10 lg kg1 buprenorphine (Car-
regaro et al. 2007; Love 2009; Love et al. 2011a,b).
However, no signs of actual colic were reported, and
locomotor stimulation is prevented when a sedative
is given with the opioid. Opioids used for equine
sedation do not appear to cause a significant problem
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with characteristics such as box walking and post-
treatment colic (Taylor et al. 1988; Browning &
Collins 1994; Love et al. 2011a).
Buprenorphine, as a mu agonist opioid, has
considerable analgesic potential. This has been
demonstrated in horses under laboratory conditions
where mechanical and thermal nociceptive thresh-
olds were raised for several hours after 5–10 lg kg1
buprenorphine (Love et al. 2012). Effective analge-
sia was also achieved with 10 lg kg1 buprenor-
phine given prior to surgical castration under
general anaesthesia (Taylor et al. 2008). Analgesic
effect was not specifically investigated in the present
study. However, the notable lack of response to
clearly painful stimuli such as skin laceration
observed in this study suggests that buprenorphine
may be a particularly appropriate opioid for standing
sedation in horses when a procedure known to be
painful is undertaken.
In conclusion, buprenorphine 5 and 10 lg kg1
enhanced the sedation produced by detomidine 10
and 20 lg kg1, enabling all procedures to be
carried out successfully. There were no serious
adverse effects but marked ataxia necessitates care-
ful handling of the horse during peak sedation.
Buprenorphine appears to be a suitable opioid for use
to enhance alpha2 adrenoceptor agonist sedation for
clinical procedures in standing horses.
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